Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03513406 · ClinicalTrials.gov registry record · Phase 3
Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery
A Phase 3 study of Burns, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT03513406: Completed Phase 3 study of Burns, sponsored by University of Kansas Medical Center.
NCT03513406 is a Phase 3 study of Burns that has completed, run by University of Kansas Medical Center. The registered enrollment target is 7 participants, below the 83-participant average among 36 other Burns trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03513406, a Phase 3 study of Burns, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn if there is a difference in recovery time when using sugammadex versus neostigmine. The researchers also hope to add further knowledge and data to the safety of using sugammadex in burn patients who are hypermetabolic.
Conditions Studied
Interventions
- DRUG Sugammadex
- DRUG Neostigmine
- DRUG Glycopyrrolate
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2023-03-07 |
| Phase | Phase 3 |
What the finished NCT03513406 record still lists
NCT03513406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 83-participant average among 36 other Burns trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Burns appearing as the primary indexed condition, and to 3 interventions - of which Sugammadex is the first listed.
NCT03513406 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03513406 about?
NCT03513406 is a clinical study titled "Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery". The purpose of this study is to learn if there is a difference in recovery time when using sugammadex versus neostigmine. The researchers also hope to add further knowledge and data to the safety of using sugammadex in burn patients who are hypermetabolic.
What is the current status of trial NCT03513406?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2018-03-15. Estimated completion is 2023-03-07.
What conditions does trial NCT03513406 study?
This clinical trial studies the following conditions: Burns.
What interventions are being tested in trial NCT03513406?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine (DRUG), Glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT03513406?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03513406 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03513406's enrollment target sits among peer trials
7 34th of 36 higher than 2 of 36 other Burns trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Burns trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
COMPLETED · Phase 3
-
Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn
COMPLETED · Phase 3
-
StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects
COMPLETED · Phase 3
-
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
RECRUITING · NA
-
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
RECRUITING · Phase 4
-
Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI